Results 61 to 70 of about 471 (127)

What do We Know so Far about Ges Carbapenemases, and What Threat do They Pose?

open access: yesPostępy Mikrobiologii
Carbapenemases, classified as bacterial enzymes, have the ability to hydrolyze carbapenems – important broad-spectrum antibiotics. This work attempts to summarize the information on the diversity of Guiana Extended-Spectrum (GES) subgroup of ...
Rutkowski Kamil   +6 more
doaj   +1 more source

Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives

open access: yes, 2023
Purpose of review Serious infections caused by nonfermenting Gram-negative bacteria (NF-GNB) pose a significant challenge for clinicians due to the limited treatment options available, which are frequently associated with issues of toxicity and ...
Daniele Roberto Giacobbe   +9 more
core   +1 more source

Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions [PDF]

open access: yes
[Abstract] Objectives: To analyse the impact of the most clinically relevant β-lactamases and their interplay with low outer membrane permeability on the activity of cefiderocol, ceftazidime/avibactam, aztreonam/avibactam, cefepime/enmetazobactam ...
Beceiro, Alejandro   +15 more
core   +2 more sources

P20 Evaluation of cefepime/enmetazobactam against MDR Enterobacterales [PDF]

open access: yesJAC Antimicrob Resist
Abstract Background Cefepime/enmetazobactam is a fourth generation cephalosporin in combination with a novel penicillanic acid sulfone ESBL inhibitor. Cefepime is stable to AmpC β-lactamases (class C) and OXA-48-like carbapenemases (class D) whilst enmetazobactam has activity against most class A β ...
Richards, J R, Wooton, M, Ward, J R
europepmc   +2 more sources

Cefepime/sulbactam combination as a treatment alternative for extended spectrum beta-lacatmase producing Enterobacterales: A multicentric study from India

open access: yesClinical Epidemiology and Global Health
Background: Piperacillin/tazobactam has limited activity against Enterobacterales, which concurrently express ESBL/ampC/OXA-1 beta-lactamases, which are widely prevalent in India.
Yamuna Devi Bakthavatchalam   +11 more
doaj   +1 more source

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications

open access: yesCurrent Therapeutic Research
Objective: This analysis aimed to provide a mechanistic understanding and an evaluation of the clinical relevance of pharmacokinetic drug-drug interactions (DDIs) associated with drugs approved by the Food and Drug Administration in 2024.
Jingjing Yu, MD, PhD   +4 more
doaj   +1 more source

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases

open access: yes
The relative inhibitory activities of diazabicyclooctanes (avibactam, relebactam, zidebactam, nacubactam, durlobactam), boronic acid derivatives (vaborbactam, taniborbactam, xeruborbactam), and penicillin-based sulfone derivative enmetazobactam were ...
Le Terrier, Christophe   +4 more
core   +1 more source

Emergence of in a single and dual-carbapenemase-producing clinical isolates of from the United Arab Emirates

open access: yesScience Progress
Objectives Carbapenem-resistant Enterobacterales have emerged as a major global health concern owing to their rapid dissemination and limited therapeutic options.
Farah Al-Marzooq   +4 more
doaj   +1 more source

Mechanistic Basis for Inhibition of the Extended Spectrum Class A β-Lactamase GES-1 by Tazobactam and Enmetazobactam

open access: yes
Abstract Expression of β-lactamases is the primary form of β-lactam antibiotic resistance in Gram-negative bacteria. Enmetazobactam is a penicillanic acid sulfone (PAS) that inhibits extended spectrum β-lactamases (ESBLs) by forming an acyl-enzyme complex that eventually breaks down to an irreversible lysinoalanine ...
Beer M   +10 more
europepmc   +2 more sources

P24 In vitro activity of cefepime/enmetazobactam, and comparators, against OXA carbapenemase-positive Acinetobacter baumannii

open access: yesJAC-Antimicrobial Resistance
Abstract Background Cefepime/enmetazobactam (FEP/META) is a new β-lactam/β-lactamase inhibitor combination with broad-spectrum activity against MDR Enterobacterales (including OXA-48-producing isolates) which has demonstrated superiority to piperacillin/tazobactam for the treatment of complicated ...
Ward, Jon   +4 more
openaire   +1 more source

Home - About - Disclaimer - Privacy